RIPK1 inhibition enhances the therapeutic efficacy of chidamide in FLT3-ITD positive AML, both in vitro and in vivo. Li J, Liao D, Wang F, Wang Z, et al. Leuk Lymphoma 2022;63:1167-1179.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Li J, Liao D, Wang F, Wang Z, et al. RIPK1 inhibition enhances the therapeutic efficacy of chidamide in FLT3-ITD positive AML, both in vitro and in vivo. Leuk Lymphoma 2022;63:1167-1179.
PMID: 34865571